Jiangxi Fushine Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Jiangxi Fushine Pharmaceutical.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.3%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

There's Reason For Concern Over Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Massive 28% Price Jump

Oct 04

Is Jiangxi Fushine Pharmaceutical (SZSE:300497) A Risky Investment?

Jun 12

What Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) 26% Share Price Gain Is Not Telling You

May 06

Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Business And Shares Still Trailing The Industry

Feb 27

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Jiangxi Fushine Pharmaceutical jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

SZSE:300497 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2024	1,300	-181	-45	102	N/A
6/30/2024	1,436	-164	-63	106	N/A
3/31/2024	1,552	-169	-78	103	N/A
12/31/2023	1,610	-201	-307	-65	N/A
9/30/2023	1,701	-269	-434	-141	N/A
6/30/2023	1,672	-246	-532	-194	N/A
3/31/2023	1,643	-200	-544	-167	N/A
1/1/2023	1,647	-141	-580	-121	N/A
9/30/2022	1,596	-66	-639	-31	N/A
6/30/2022	1,485	-58	-728	-28	N/A
3/31/2022	1,437	2	-723	-13	N/A
1/1/2022	1,430	49	-607	72	N/A
9/30/2021	1,450	187	-407	203	N/A
6/30/2021	1,452	252	-298	263	N/A
3/31/2021	1,521	310	-212	335	N/A
12/31/2020	1,493	319	-67	382	N/A
9/30/2020	1,496	383	59	447	N/A
6/30/2020	1,578	411	135	459	N/A
3/31/2020	1,426	336	151	411	N/A
12/31/2019	1,354	306	13	338	N/A
9/30/2019	1,238	238	-61	224	N/A
6/30/2019	1,134	177	-44	196	N/A
3/31/2019	1,154	186	-79	171	N/A
12/31/2018	1,163	195	12	176	N/A
9/30/2018	1,147	211	52	187	N/A
6/30/2018	1,106	208	N/A	184	N/A
3/31/2018	1,033	189	N/A	186	N/A
12/31/2017	958	178	N/A	211	N/A
9/30/2017	906	182	N/A	216	N/A
6/30/2017	875	189	N/A	192	N/A
3/31/2017	834	188	N/A	192	N/A
12/31/2016	764	174	N/A	189	N/A
9/30/2016	705	161	N/A	151	N/A
6/30/2016	667	139	N/A	110	N/A
3/31/2016	606	111	N/A	102	N/A
12/31/2015	580	94	N/A	74	N/A
3/31/2015	530	60	N/A	44	N/A
12/31/2014	511	53	N/A	31	N/A
12/31/2013	443	45	N/A	57	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 300497's forecast earnings growth is above the savings rate (2.9%).

Ertrag vs. Markt: Insufficient data to determine if 300497's earnings are forecast to grow faster than the CN market

Hohe Wachstumserträge: Insufficient data to determine if 300497's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if 300497's revenue is forecast to grow faster than the CN market.

Hohe Wachstumseinnahmen: Insufficient data to determine if 300497's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 300497's Return on Equity is forecast to be high in 3 years time

Jiangxi Fushine Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Third quarter 2024 earnings released: CN¥0.092 loss per share (vs CN¥0.04 loss in 3Q 2023)

There's Reason For Concern Over Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Massive 28% Price Jump

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024

New major risk - Financial data availability

Second quarter 2024 earnings released: CN¥0.038 loss per share (vs CN¥0.051 loss in 2Q 2023)

New minor risk - Share price stability

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Is Jiangxi Fushine Pharmaceutical (SZSE:300497) A Risky Investment?

What Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) 26% Share Price Gain Is Not Telling You

Jiangxi Fushine Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: CN¥0.37 loss per share (vs CN¥0.26 loss in FY 2022)

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Business And Shares Still Trailing The Industry

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding

Third quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.001 profit in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: CN¥0.051 loss per share (vs CN¥0.03 profit in 2Q 2022)

First quarter 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.05 profit in 1Q 2022)

Third quarter 2022 earnings released: EPS: CN¥0.001 (vs CN¥0.017 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.14 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.017 (vs CN¥0.16 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.29 in 2Q 2020)

Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) announces an Equity Buyback for CNY 200 million worth of its shares.

Jiangxi Fushine Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020

Jiangxi Fushine Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020 Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.70 (vs CN¥0.71 in FY 2019)

New 90-day low: CN¥13.03

New 90-day low: CN¥13.73

Market pulls back on stock over the past week

New 90-day low: CN¥15.64

Third quarter earnings released

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low: CN¥17.20

Jiangxi Fushine Pharmaceutical Co., Ltd. cancelled the transaction announced on March 30, 2020

New 90-day high - CN¥22.57

Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.06415 billion in funding

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 05, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken